Medscape November 4, 2024
(Reuters) – Americans are still eagerly seeking prescriptions for Eli Lilly and Novo Nordisk’s weight-loss and diabetes drugs but cannot always fill them because of supply issues and insurance hurdles, according to their doctors.
Those frustrations, along with the medicines’ high cost, are pushing patients to cheaper compounded versions sold online, doctors, pharmacy officials and Wall Street analysts said.
Lilly last week reported a rare $1.5 billion sales miss for its injectable obesity drug Zepbound and diabetes medicine Mounjaro combined, raising concerns among investors that demand might be cooling for the products. Those market dynamics will again be in focus when Novo reports results for its diabetes drug Ozempic and weight-loss medicine Wegovy this Wednesday.
Lilly attributed the shortfall to...
Today's Sponsors
Today's Sponsor